{
    "organizations": [],
    "uuid": "b9989e4e97a5726778e75bf28d7ce68774507e93",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novimmune-submits-biologics-licens/brief-novimmune-submits-biologics-license-application-in-us-for-its-lead-drug-emapalumab-idUSFWN1RA121",
    "ord_in_thread": 0,
    "title": "Novimmune ‍Submits Biologics License Application In US For Its Lead Drug Emapalumab​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29 (Reuters) - NOVIMMUNE SA ( IPO-NOVI.S ):\n* ‍SUBMITS BIOLOGICS LICENSE APPLICATION IN US FOR ITS LEAD DRUG EMAPALUMAB​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-29T13:11:00.000+03:00",
    "crawled": "2018-03-30T13:14:47.087+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "novimmune",
        "sa",
        "biologics",
        "license",
        "application",
        "u",
        "lead",
        "drug",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}